212 related articles for article (PubMed ID: 8908072)
1. Cytomegalovirus prophylaxis by ganciclovir followed by high-dose acyclovir in renal transplantation: a randomized, controlled trial.
Pouteil-Noble C; Megas F; Chapuis F; Bosshard S; Colin C; Hadj-Aissa A; Pozet N; Martin X; Lefrançois N; Garnier JL; Aymard M; Touraine JL
Transplant Proc; 1996 Oct; 28(5):2811. PubMed ID: 8908072
[No Abstract] [Full Text] [Related]
2. Cytomegalovirus infection in kidney transplantation: prophylaxis and management.
Bulinski P; Toledo-Pereyra LH; Dalal S; Hernandez G
Transplant Proc; 1996 Dec; 28(6):3310-1. PubMed ID: 8962286
[No Abstract] [Full Text] [Related]
3. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of combination prophylaxis with cytomegalovirus hyperimmune globulin and acyclovir in the high-risk kidney transplant recipient.
Uber L; Cofer J; Baliga P; Rajagopalan PR
Transplant Proc; 1995 Oct; 27(5 Suppl 1):42-3. PubMed ID: 7482818
[No Abstract] [Full Text] [Related]
5. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
Winston DJ; Busuttil RW
Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
[TBL] [Abstract][Full Text] [Related]
6. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
[TBL] [Abstract][Full Text] [Related]
7. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
[TBL] [Abstract][Full Text] [Related]
8. Ganciclovir/acyclovir prophylaxis reduces the incidence of cytomegalovirus infections in pancreas transplant recipients.
Harland RC; Vernon WB; Bunzendahl H; Thompson JK; Lawrence C; Bollinger RR
Transplant Proc; 1994 Apr; 26(2):432-3. PubMed ID: 8171488
[No Abstract] [Full Text] [Related]
9. Viral prophylaxis in hepatic transplantation: preliminary report of a randomized trial of acyclovir and gancyclovir.
Nakazato PZ; Burns W; Moore P; Garcia-Kennedy R; Cox K; Esquivel C
Transplant Proc; 1993 Apr; 25(2):1935-7. PubMed ID: 7682357
[No Abstract] [Full Text] [Related]
10. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
[TBL] [Abstract][Full Text] [Related]
11. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
[TBL] [Abstract][Full Text] [Related]
12. Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing anti-lymphocyte globulin treatment for acute rejection.
Dickenmann MJ; Kabulbayev K; Steiger J; Cathomas G; Reusser P; Tamm M
Clin Microbiol Infect; 2004 Apr; 10(4):337-9. PubMed ID: 15059125
[TBL] [Abstract][Full Text] [Related]
13. Ganciclovir prophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients.
Israni A; Krok K; Cohen D; Blumberg E; Bloom RD
Transplant Proc; 2004 Dec; 36(10):3019-24. PubMed ID: 15686685
[TBL] [Abstract][Full Text] [Related]
14. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
15. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection.
Reischig T; Jindra P; Svecová M; Kormunda S; Opatrný K; Treska V
J Clin Virol; 2006 Jun; 36(2):146-51. PubMed ID: 16531113
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus infection in kidney transplant recipients: Evolution of approach through three eras.
Boucher A; Lord H; Collette S; Morin M; Dandavino R
Transplant Proc; 2006 Dec; 38(10):3506-8. PubMed ID: 17175316
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus disease prophylaxis in renal transplantation by high dose oral acyclovir: efficacy and limits.
Bertoni E; Rosati A; Zanazzi M; Moscarelli L; Di Maria L; Piperno R; Orsi A; Parri F; Dedola G; Salvadori M
Transplant Proc; 1998 Aug; 30(5):2094. PubMed ID: 9723402
[No Abstract] [Full Text] [Related]
18. Superior efficacy of oral ganciclovir over oral acyclovir for cytomegalovirus prophylaxis in kidney-pancreas and pancreas alone recipients.
Somerville T; Hurst G; Alloway R; Gaber A; Shokouh-Amiri MH; Stratta R
Transplant Proc; 1998 Jun; 30(4):1546-8. PubMed ID: 9636628
[No Abstract] [Full Text] [Related]
19. [The significance of risk-adapted antiviral prophylaxis and modern viral diagnosis for organ survival after kidney transplantation].
Bach D; Will A; Grabensee B; Krempe C
Dtsch Med Wochenschr; 1997 Oct; 122(43):1334. PubMed ID: 9410702
[No Abstract] [Full Text] [Related]
20. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
